



Disposals of own shares

Brussels (Belgium), 2 July 2021 – 20:00 (CEST) – regulated information

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

| Date of transaction | Time | LTI Plan | Number of disposed UCB shares | Price |
|------------------------|----------|------------------------|----------------------------------|---------|
| 25 June 2021 | 11:39:00 | Stock Option Plan 2014 | 1.075 | € 58,12 |
| 25 June 2021 | 11:50:44 | Stock Option Plan 2012 | 170 | € 32,36 |
| 25 June 2021 | 13:32:05 | Stock Option Plan 2013 | 400 | € 48,69 |
| 25 June 2021 | 14:02:40 | Stock Option Plan 2012 | 3.500 | € 32,36 |
| 25 June 2021 | 16:32:21 | Stock Option Plan 2012 | 1.500 | € 32,36 |
| 28 June 2021 | 09:49:20 | Stock Option Plan 2017 | 1.100 | € 70,26 |
| 28 June 2021 | 11:09:54 | Stock Option Plan 2017 | 1.500 | € 70,26 |
| 28 June 2021 | 15:40:50 | Stock Option Plan 2012 | 200 | € 32,36 |
| 30 June 2021 | 11:53:48 | Stock Option Plan 2018 | 518 | € 66,18 |

In addition to these exercises, on 1 July 2021, in accordance with its Stock Award Plan 2020, UCB SA/NV has delivered for free 335 UCB shares OTC to two members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 1 July 2021 was € 89,64.

This press release is available on UCB SA/NV's website via the following link.



Investor Relations

Antje Witte, Investor Relations, UCB

T +32 2 559 94 14, antje.witte@ucb.com

Corporate Communications

Laurent Schots Media Relations, UCB

T+32.2.559.92.64 laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of \in 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

